Search Results 21-30 of 37569 for Two-phase
Study ACT16970 consists of 2 parts (A and B) as follows: Part A is a 24 week, double blind, placebo controlled part, preceded by a screening period of up to 4 ...
Phase 2, 80 new subjects will be randomized in a 1:1 ratio into 2 doses/schedules. Participation eligibility. Participant eligibility includes age, gender, type ...
The purpose of this study is to evaluate the efficacy and safety of two different dosing regimens of AP26113 in patients with anaplastic lymphoma kinase (ALK)- ...
About this study. This is an adaptive clinical trial that includes a dose escalation phase followed by a randomized controlled Phase 3 trial.
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients with ALS · More about research at Mayo Clinic.
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage ...
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in NMIBC · Overview · Participation eligibility · Participating Mayo Clinic ...
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus · Overview.
Clinical Trials · A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction · More about research at Mayo Clinic.
Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.